

# Jens Ulrik S Jensen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9113539/publications.pdf>

Version: 2024-02-01

107  
papers

4,068  
citations

236925

25  
h-index

128289

60  
g-index

109  
all docs

109  
docs citations

109  
times ranked

5539  
citing authors

#	ARTICLE	IF	CITATIONS
1	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , 2022, 59, 2100752.	6.7	31
2	Biomarkers in Chronic Obstructive Pulmonary Disease: Emerging Roles of Eosinophils and Procalcitonin. <i>Journal of Innate Immunity</i> , 2022, 14, 89-97.	3.8	4
3	Use of inhaled corticosteroids and risk of acquiring <i>Pseudomonas aeruginosa</i> in patients with chronic obstructive pulmonary disease. <i>Thorax</i> , 2022, 77, 573-580.	5.6	26
4	ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations. <i>European Respiratory Journal</i> , 2022, 59, 2102006.	6.7	34
5	Long-term cognitive and pulmonary functions following a lower versus a higher oxygenation target in the HOT-ICU trial: protocol and statistical analysis plan. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, 66, 282-287.	1.6	3
6	Lung Ultrasound Findings Associated With COVID-19 ARDS, ICU Admission, and All-Cause Mortality. <i>Respiratory Care</i> , 2022, 67, 66-75.	1.6	7
7	Social Distancing in Relation to Severe Exacerbations of Chronic Obstructive Pulmonary Disease: A Nationwide Semi-Experimental Study During the COVID-19 Pandemic. <i>American Journal of Epidemiology</i> , 2022, 191, 874-885.	3.4	11
8	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet, The</i> , 2022, 399, 530-540.	13.7	48
9	Persistence and genetic adaptation of <i>Pseudomonas aeruginosa</i> in patients with chronic obstructive pulmonary disease. <i>Clinical Microbiology and Infection</i> , 2022, 28, 990-995.	6.0	9
10	Flu Vaccine and Mortality in Hypertension: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2022, , e021715.	3.7	4
11	Adrenal suppression in patients with chronic obstructive pulmonary disease treated with glucocorticoids: Role of specific glucocorticoid receptor polymorphisms. <i>PLoS ONE</i> , 2022, 17, e0262898.	2.5	3
12	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
13	Biomarker bei chronisch-obstruktiven Lungenerkrankungen: Zunehmende Rolle von Eosinophilen und Procalcitonin. <i>Karger Kompass Pneumologie</i> , 2022, 10, 52-59.	0.0	0
14	The feasibility of pragmatic influenza vaccine randomized controlled real-world trials in Denmark and England. <i>Npj Vaccines</i> , 2022, 7, 25.	6.0	3
15	Intrapleural fibrinolysis and DNase versus video-assisted thoracic surgery (VATS) for the treatment of pleural empyema (FIVERVATS): protocol for a randomised, controlled trial – surgery as first-line treatment. <i>BMJ Open</i> , 2022, 12, e054236.	1.9	4
16	Lung ultrasound findings following COVID-19 hospitalization: A prospective longitudinal cohort study. <i>Respiratory Medicine</i> , 2022, 197, 106826.	2.9	7
17	Feasibility of randomizing Danish citizens aged 65–79 years to high-dose quadrivalent influenza vaccine vs. standard-dose quadrivalent influenza vaccine in a pragmatic registry-based setting: rationale and design of the DANFLU-1 Trial. <i>Pilot and Feasibility Studies</i> , 2022, 8, 87.	1.2	8
18	The Impact of Social Distancing in 2020 on Admission Rates for Exacerbations in Asthma: A Nationwide Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2086-2092.e2.	3.8	5

#	ARTICLE	IF	CITATIONS
19	Clinical impact of vital sign abnormalities in patients admitted with acute exacerbation of chronic obstructive pulmonary disease: an observational study using continuous wireless monitoring. <i>Internal and Emergency Medicine</i> , 2022, 17, 1689-1698.	2.0	6
20	Recent developments in the management of severe asthma. <i>Breathe</i> , 2022, 18, 210178.	1.3	1
21	Use of Inhaled Corticosteroids and Risk of Acquiring <i>Haemophilus influenzae</i> in Patients with Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 3539.	2.4	5
22	Risk of Malignancy in Patients with Asthma-COPD Overlap Compared to Patients with COPD without Asthma. <i>Biomedicines</i> , 2022, 10, 1463.	3.2	2
23	High-pressure NIV for acute hypercapnic respiratory failure in COPD: improved survival in a retrospective cohort study. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001260.	3.0	1
24	Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 COVID-19 vaccination in patients with chronic pulmonary diseases. <i>BMJ Open Respiratory Research</i> , 2022, 9, e001268.	3.0	7
25	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	27.0	357
26	How are rapid diagnostic tests for infectious diseases used in clinical practice: a global survey by the International Society of Antimicrobial Chemotherapy (ISAC). <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 429-434.	2.9	6
27	Characteristics, interventions, and longer term outcomes of COVID-19 ICU patients in Denmark: A nationwide, observational study. <i>Acta Anaesthesiologica Scandinavica</i> , 2021, 65, 68-75.	1.6	64
28	Antibiotic treatment in acute exacerbation of COPD: patient outcomes with amoxicillin vs. amoxicillin/clavulanic acid: data from 43,636 outpatients. <i>Respiratory Research</i> , 2021, 22, 11.	3.6	3
29	Using Blood Eosinophil Count as a Biomarker to Guide Corticosteroid Treatment for Chronic Obstructive Pulmonary Disease. <i>Diagnostics</i> , 2021, 11, 236.	2.6	12
30	Does inhaled corticosteroid use affect the risk of COVID-19-related death?. <i>Breathe</i> , 2021, 17, 200275.	1.3	4
31	Withdrawal of Inhaled Corticosteroids in Patients with COPD: A Prospective Observational Study. <i>International Journal of COPD</i> , 2021, Volume 16, 807-815.	2.3	4
32	ABO blood types and sepsis mortality. <i>Annals of Intensive Care</i> , 2021, 11, 61.	4.6	5
33	Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. <i>Respiratory Research</i> , 2021, 22, 155.	3.6	5
34	Risk of Chronic Obstructive Pulmonary Disease Exacerbation in Patients Who Use Methotrexate: A Nationwide Study of 58,580 Outpatients. <i>Biomedicines</i> , 2021, 9, 604.	3.2	2
35	Corticosteroid Resistance in Smokers: A Substudy Analysis of the CORTICO-COP Randomised Controlled Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 2734.	2.4	0
36	Cardiac arrhythmias in patients hospitalized with COVID-19: The ACOVID study. <i>Heart Rhythm O2</i> , 2021, 2, 304-308.	1.7	10

#	ARTICLE	IF	CITATIONS
37	Heart failure associated with imported malaria: a nationwide Danish cohort study. <i>ESC Heart Failure</i> , 2021, 8, 3521-3529.	3.1	9
38	Systemic Corticosteroids and the Risk of Venous Thromboembolism in Patients with Severe COPD: A Nationwide Study of 30,473 Outpatients. <i>Biomedicines</i> , 2021, 9, 874.	3.2	4
39	Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study. <i>International Journal of Infectious Diseases</i> , 2021, 108, 370-376.	3.3	5
40	Lung ultrasound findings in hospitalized COVID-19 patients in relation to venous thromboembolic events: the ECHOVID-19 study. <i>Journal of Ultrasound</i> , 2021, , 1.	1.3	1
41	Recovery of cardiac function following COVID-19: A prospective longitudinal cohort study. <i>European Journal of Heart Failure</i> , 2021, 23, 1903-1912.	7.1	40
42	Treatment Response Biomarkers in Asthma and COPD. <i>Diagnostics</i> , 2021, 11, 1668.	2.6	5
43	Novel Perspectives Regarding the Pathology, Inflammation, and Biomarkers of Acute Respiratory Distress Syndrome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 205.	4.1	8
44	The Association between Use of ICS and Psychiatric Symptoms in Patients with COPD: A Nationwide Cohort Study of 49,500 Patients. <i>Biomedicines</i> , 2021, 9, 1492.	3.2	3
45	Management of COVID-19-Associated Acute Respiratory Failure with Alternatives to Invasive Mechanical Ventilation: High-Flow Oxygen, Continuous Positive Airway Pressure, and Noninvasive Ventilation. <i>Diagnostics</i> , 2021, 11, 2259.	2.6	21
46	Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study. <i>Biomedicines</i> , 2021, 9, 1837.	3.2	6
47	Physiological abnormalities in patients admitted with acute exacerbation of COPD: an observational study with continuous monitoring. <i>Journal of Clinical Monitoring and Computing</i> , 2020, 34, 1051-1060.	1.6	19
48	Acute COVID-19 and the Incidence of Ischemic Stroke and Acute Myocardial Infarction. <i>Circulation</i> , 2020, 142, 2080-2082.	1.6	168
49	Bone turnover biomarkers in COPD patients randomized to either a regular or shortened course of corticosteroids: a substudy of the randomized controlled CORTICO-COP trial. <i>Respiratory Research</i> , 2020, 21, 263.	3.6	1
50	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , 2020, 43, 2226-2233.	8.6	36
51	Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study. <i>ESC Heart Failure</i> , 2020, 7, 4189-4197.	3.1	77
52	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. <i>Trials</i> , 2020, 21, 867.	1.6	6
53	Roflumilast in Severely Ill Patients with Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Risk of Pneumonia Hospitalization and Severe Exacerbations. <i>Journal of Clinical Medicine</i> , 2020, 9, 1442.	2.4	2
54	Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , 2020, 21, 513.	1.6	10

#	ARTICLE	IF	CITATIONS
55	Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1761677.	1.5	26
56	Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1348-1356.	4.4	19
57	Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. <i>Thorax</i> , 2020, 75, 520-527.	5.6	97
58	Myocardial Impairment and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2474-2476.	5.3	10
59	Depressive symptoms among patients with COPD according to smoking status: a Danish nationwide case-control study of 21 184 patients. <i>ERJ Open Research</i> , 2020, 6, 00036-2020.	2.6	3
60	Core outcome set for the management of acute exacerbations of chronic obstructive pulmonary disease: the COS-AECOPD ERS Task Force study protocol. <i>ERJ Open Research</i> , 2020, 6, 00193-2020.	2.6	14
61	Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. <i>The Cochrane Library</i> , 2019, 2019, CD007498.	2.8	320
62	Biomarkers of Acute Lung Injury The Individualized Approach: for Phenotyping, Risk Stratification and Treatment Surveillance. <i>Journal of Clinical Medicine</i> , 2019, 8, 1163.	2.4	16
63	Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 686-696.	2.5	12
64	Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 699-709.	10.7	111
65	Procalcitonin in acute infections: from the research laboratory to clinical impact new perspectives of biomarker use. <i>Journal of Laboratory and Precision Medicine</i> , 2019, 4, 36-36.	1.1	2
66	Non-eosinophilic severe exacerbations of COPD: what about antibiotics? Authors' reply. <i>Lancet Respiratory Medicine</i> , 2019, 7, e34.	10.7	3
67	Acute Lung Injury in Critically Ill Patients: Actin-Scavenger Gelsolin Signals Prolonged Respiratory Failure. <i>Shock</i> , 2019, 52, 370-377.	2.1	9
68	Biomarker-assisted identification of sepsis-related acute liver impairment: a frequent and deadly condition in critically ill patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1422-1431.	2.3	11
69	COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000407.	3.0	47
70	Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1308-1318.	2.3	182
71	Antibiotic treatment adequacy and death among patients with <i>Pseudomonas aeruginosa</i> airway infection. <i>PLoS ONE</i> , 2019, 14, e0226935.	2.5	9
72	Procalcitonin-guided Antibiotic Treatment in Patients With Positive Blood Cultures: A Patient-level Meta-analysis of Randomized Trials. <i>Clinical Infectious Diseases</i> , 2019, 69, 388-396.	5.8	66

#	ARTICLE	IF	CITATIONS
73	Induced hypothermia in patients with septic shock and respiratory failure (CASS): a randomised, controlled, open-label trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 183-192.	10.7	51
74	Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. <i>Lancet Infectious Diseases</i> , 2018, 18, 95-107.	9.1	337
75	Automated oxygen control with O2matic <sup>®</sup> during admission with exacerbation of COPD. <i>International Journal of COPD</i> , 2018, Volume 13, 3997-4003.	2.3	19
76	Danish respiratory society position paper: palliative care in patients with chronic progressive non-malignant lung diseases. <i>European Clinical Respiratory Journal</i> , 2018, 5, 1530029.	1.5	13
77	Sepsis: Personalized Medicine Utilizing "Omicron" Technologies? A Paradigm Shift?. <i>Healthcare (Switzerland)</i> , 2018, 6, 111.	2.0	20
78	Predicting recovery from acute kidney injury in critically ill patients: development and validation of a prediction model. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , 2018, 20, 54-60.	0.1	7
79	Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. <i>Shock</i> , 2017, 47, 696-701.	2.1	17
80	Self-Rated Health as a Predictor of Death after Two Years: The Importance of Physical and Mental Wellbeing Postintensive Care. <i>BioMed Research International</i> , 2017, 2017, 1-8.	1.9	12
81	Point-of-care procalcitonin test to reduce antibiotic exposure in patients hospitalized with acute exacerbation of COPD. <i>International Journal of COPD</i> , 2016, 11, 1381.	2.3	47
82	Biomarker-guided antibiotic use in primary care in resource-constrained environments. <i>The Lancet Global Health</i> , 2016, 4, e586-e587.	6.3	7
83	Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. <i>Annals of Intensive Care</i> , 2016, 6, 114.	4.6	14
84	Why biomarkers failed in sepsis. <i>Intensive Care Medicine</i> , 2016, 42, 2049-2051.	8.2	29
85	Hyaluronic Acid Assays: Turbidimetric or Enzyme-Based Immune Assay? A Method Comparison Study. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 524-528.	2.1	3
86	The author replies. <i>Critical Care Medicine</i> , 2015, 43, e323.	0.9	0
87	Timing of Therapy in Sepsis. <i>Critical Care Medicine</i> , 2015, 43, 2030-2031.	0.9	4
88	Readmission After Intensive Care. <i>Critical Care Medicine</i> , 2015, 43, 504-505.	0.9	4
89	Profound Endothelial Damage Predicts Impending Organ Failure and Death in Sepsis. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 016-025.	2.7	79
90	Invasive Candida Infections and the Harm From Antibacterial Drugs in Critically Ill Patients. <i>Critical Care Medicine</i> , 2015, 43, 594-602.	0.9	39

#	ARTICLE	IF	CITATIONS
91	Non-recognized Liver Impairment in Infected Critically Ill Patients Is Frequent and Hazardous. Open Forum Infectious Diseases, 2015, 2, .	0.9	1
92	Cytomegalovirus (CMV) Viral Load in Bronchoalveolar Lavage Fluid and Plasma to Diagnose Lung-Transplant Associated CMV Pneumonia. Open Forum Infectious Diseases, 2015, 2, .	0.9	0
93	Novel Biomarkers of Infection in Critically Ill Cancer Patients. Critical Care Medicine, 2014, 42, 2632-2633.	0.9	0
94	Serum and Plasma Neutrophil Gelatinase Associated Lipocalin (NGAL) Levels are Not Equivalent in Patients Admitted to Intensive Care. Journal of Clinical Laboratory Analysis, 2014, 28, 163-167.	2.1	12
95	Biomarkers as point-of-care tests to guide prescription of antibiotics in patients with acute respiratory infections in primary care. The Cochrane Library, 2014, , CD010130.	2.8	134
96	Biomarker-guided clinical decisions: for patients, health economists or neither?. European Respiratory Journal, 2013, 42, 895-897.	6.7	0
97	The Potential of Antimicrobials to Induce Thrombocytopenia in Critically Ill Patients: Data from a Randomized Controlled Trial. PLoS ONE, 2013, 8, e81477.	2.5	16
98	Kidney failure related to broad-spectrum antibiotics in critically ill patients: secondary end point results from a 1200 patient randomised trial. BMJ Open, 2012, 2, e000635.	1.9	77
99	Refinement of prompts for rapid response teams*. Critical Care Medicine, 2012, 40, 2241-2242.	0.9	0
100	To escalate or to de-escalate? That is the question. Critical Care Medicine, 2011, 39, 2591.	0.9	0
101	Antibiotics in intensive care: Too little or too much?*. Critical Care Medicine, 2011, 39, 1849-1851.	0.9	14
102	Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet?. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2011, 20, 360-367.	2.3	20
103	Procalcitonin monitoring in trauma intensive care patients: How helpful is it?*. Critical Care Medicine, 2009, 37, 2093-2094.	0.9	6
104	The Procalcitonin And Survival Study (PASS) – A Randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. BMC Infectious Diseases, 2008, 8, 91.	2.9	37
105	Procalcitonin in liver transplant patients – yet another stone turned. Critical Care, 2008, 12, 108.	5.8	4
106	Meta-analysis of procalcitonin for sepsis detection. Lancet Infectious Diseases, The, 2007, 7, 499-500.	9.1	8
107	Procalcitonin increase in early identification of critically ill patients at high risk of mortality*. Critical Care Medicine, 2006, 34, 2596-2602.	0.9	901